SAN DIEGO, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that Scott Struthers, Ph.D., founder and chief executive officer of Crinetics, will present at the 42nd Annual J.P. Morgan Healthcare Conference, which is taking place in San Francisco, CA from January 8-11, 2024.
Details of the corporate presentation are as follows:
| Date: | Tuesday, January 9, 2024 |
| Time: | 3:45 p.m. Pacific Time |
| Room: | Borgia Room |
The live and archived webcast will be accessible on the Events & Presentations page in the Investors section on the Crinetics’ website at www.crinetics.com/events.
If you are interested in arranging a 1×1 meeting with management, please contact your J.P. Morgan representative.
About Crinetics Pharmaceuticals
Crinetics Pharmaceuticals is a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors. Paltusotine, an investigational, first-in-class, oral somatostatin receptor type 2 (SST2) agonist, is in Phase 3 clinical development for acromegaly and Phase 2 clinical development for carcinoid syndrome associated with neuroendocrine tumors. Crinetics has demonstrated pharmacologic proof-of-concept in a Phase 1 clinical study for CRN04894, a first-in-class, investigational, oral ACTH antagonist, that is currently in Phase 2 clinical studies for the treatment of Cushing’s disease and congenital adrenal hyperplasia. All of the company’s drug candidates are orally delivered, small molecule new chemical entities resulting from in-house drug discovery efforts, including additional discovery programs addressing a variety of endocrine conditions such as hyperparathyroidism, polycystic kidney disease, Graves’ disease, thyroid eye disease, hyperinsulinism, diabetes and obesity.
Investors:
Chas Schultz
VP, Investor Relations
This email address is being protected from spambots. You need JavaScript enabled to view it.
(858) 450-6464
Corey Davis
LifeSci Advisors
This email address is being protected from spambots. You need JavaScript enabled to view it.
(212) 915-2577
Media:
Natalie Badillo
Head of Corporate Communications
This email address is being protected from spambots. You need JavaScript enabled to view it.
(858) 450-6464
| Last Trade: | US$34.67 |
| Daily Change: | 0.49 1.43 |
| Daily Volume: | 922,753 |
| Market Cap: | US$3.220B |
February 27, 2025 January 10, 2025 December 09, 2024 November 12, 2024 | |
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORE
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
